We recently published a list of 10 Stocks With At Least $20 Million In Insider Spending Recently. In this article, we are ...

Tectonic recently announced its third-quarter 2024 financial results, highlighting signif Phase 1a results support further development of TX000045 (“TX45”) for Group 2 Pulmonary Hypertension i ...

Tectonic reported that TX45 achieved a 17.9% reduction in Pulmonary Capillary Wedge Pressure (PCWP) across the study population. Moreover, in a subset of patients with more severe disease, known ...

Tenax Therapeutics said it will extend its Phase 3 clinical development of an oral form of levosimendan for pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). Tenax ...

Blocking GLS1, an enzyme that drives pro-inflammatory immune macrophages, reduces the signs and symptoms of pulmonary arterial hypertension (PAH) in rats, a study reports. “This study offers a fresh ...

After hours: March 3 at 6:04:26 PM EST ...

After hours: February 28 at 6:50:53 p.m. EST ...